Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.
No hay suficientes datos históricos para mostrar el gráfico de HIMS.
Precio
$ 11.220
Var. %
+0,35%
Volumen operado
50.894
Precio HIMS
US$ 27,82
Teórico (precio / ratio)
HIMS ÷ 4
US$ 6,96
Sí, existe el CEDEAR de HIMS (Hims & Hers Health, Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es HIMS.
El ticker del CEDEAR de Hims & Hers Health, Inc. en Argentina es HIMS. La acción subyacente cotiza en NYSE con el símbolo HIMS.
El CEDEAR HIMS tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de HIMS.
El CEDEAR HIMS cotiza hoy a $ 11.220 en pesos argentinos, con una variación diaria de +0,35%.
Yahoo · 14 de oct de 2026
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.72, denoting a -6.7% move from the preceding trading day.
Yahoo · 14 de oct de 2026
HIMS expands into Australia's women's healthcare market with the Hers launch, offering personalized treatments for weight, hormonal health and hair regrowth.
SeekingAlpha · 14 de oct de 2026
Cencora (COR) may gain from AI-driven prescribing volume growth; with strong operating leverage and discounted P/E, see risks and $365 targetâread now.
Cotización
US$ 7,15
vs teórico
+2,8%
Cotización MEP implícita
$ 1.569,23
Cotización
US$ 7,41
vs teórico
+6,54%
Cotización Cable implícita
$ 1.514,17
La acción subyacente HIMS (Hims & Hers Health, Inc.) cotiza a US$ 27,82 en su mercado de origen (NYSE).
El precio teórico del CEDEAR HIMS se calcula dividiendo el precio de HIMS por el ratio (4). Hoy resulta en US$ 6,96.
En BYMA podés operar HIMS en pesos, HIMSD en dólar MEP y HIMSC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR HIMS en pesos argentinos, con datos de data912.
SeekingAlpha · 13 de oct de 2026
Hims & Hers Health is rated a buy, with a fair value estimate of $41 per share versus the current $29.81. Read more on HIMS stock here.
Yahoo · 12 de oct de 2026
Investors holding Hims & Hers Health (HIMS) face a stark contradiction. The stock has lost 52% in twelve months, while the S&P 500 returned 17.0%. Following tha…
Yahoo · 12 de oct de 2026
SAN FRANCISCO, October 12, 2026--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading global health and wellness platform, today announced that it…
Yahoo · 12 de oct de 2026
SYDNEY, October 12, 2026--Hims & Hers, the leading global health and wellness platform, today announced the official launch of Hers in Australia, bringing its p…
Yahoo · 12 de oct de 2026
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value…
Noticias vía Finnhub